PTC Therapeutics filings document a Delaware biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under PTCT. Its Form 8-K reports cover quarterly and annual financial results, Regulation FD disclosures, product and pipeline updates, FDA-related communications, and board or compensation matters.
Proxy materials describe annual meeting governance, director elections, executive compensation, equity awards and related shareholder matters. The filing record also includes disclosures tied to rare-disease programs such as Sephience™ (sepiapterin), votoplam and Translarna™ (ataluren), along with the company’s capital structure and public-company reporting obligations.
An insider has filed a notice to sell 2,266 shares of common stock through Fidelity Brokerage Services, with an aggregate market value of $172,216.00. The planned sale is targeted for 01/05/2026 on the NASDAQ market. These shares were acquired on 01/05/2026 via a stock option originally granted on 01/05/2023, and paid for in cash. In the past three months, the same person sold additional common shares in three transactions totaling several thousand shares, while total shares outstanding are 80,288,305.
PTC Therapeutics director reports stock option exercise and share acquisition. A board member exercised a stock option on 12/16/2025 to acquire 24,000 shares of PTC Therapeutics common stock at an exercise price of $30.86 per share. The transaction is coded "M," indicating an option exercise. Following this transaction, the director beneficially owns 155,266 shares of common stock held directly. The exercised option covered 24,000 shares, was noted as currently exercisable, and carries an expiration date of 01/03/2026.
PTC Therapeutics, Inc. director reports option exercise and share sale. On 12/03/2025, the director exercised a stock option for 733 shares of common stock at $46.54 per share and then sold 733 common shares at $78.62 per share. After these transactions, the director directly beneficially owned 6,666 shares of PTC Therapeutics common stock.
The stock option exercised on that date had a conversion price of $46.54 and relates to 733 underlying common shares. Following the transaction, the director held 734 derivative securities (stock options) expiring on 01/02/2035. The filing notes that the transaction was effected under a written Rule 10b5-1 trading plan adopted on March 4, 2025, which is designed to standardize trading and help address trading‑window and insider‑trading concerns.
PTC Therapeutics, Inc. (PTCT) reported insider activity by its Chief Technical Operations Officer. On 11/24/2025, the executive exercised several stock options to buy common stock at exercise prices of $18.01 and $33.02 per share and, on the same date, sold corresponding shares of common stock in multiple transactions at weighted average prices around $80 per share, with specific ranges disclosed for each sale.
The transactions were carried out under a written Rule 10b5-1 trading plan adopted on December 10, 2024, which is intended to provide an affirmative defense for pre-planned trades. Following the reported transactions, the executive beneficially owned 100,625 shares of PTCT common stock directly and an additional 6,179 shares indirectly through a spouse. Certain stock options reported in the filing are noted as currently exercisable, with stated expiration dates in 2028 and 2029.
PTC Therapeutics (PTCT) director reports option exercises and stock sales. A board member exercised stock options on 11/24/2025 and 11/25/2025 at exercise prices of $11.23 and $18.01 per share, converting options into common stock. On the same dates, the director sold shares in multiple transactions at weighted average prices generally between the low $80 and mid $80 per share. After these transactions, the director directly owned 17,451 shares of PTC Therapeutics common stock. The filing states that the trades were carried out under a written Rule 10b5-1 trading plan adopted on March 12, 2025.
PTC Therapeutics director reports stock option exercise and sale. A board member of PTC Therapeutics, Inc. (PTCT) exercised stock options for 10,000 shares of common stock at an exercise price of $51.16 per share on 11/21/2025. On the same day, the director sold 10,000 shares of common stock at a price of $79.50 per share. After these transactions, the director beneficially owned 6,666 shares of PTCT common stock directly. The option exercise was reported as a stock option (right to buy) that was already exercisable and carries an expiration date of 01/28/2030. The filing notes that the transactions were carried out under a pre‑established Rule 10b5‑1 trading plan adopted on March 4, 2025, which is designed to allow trading under predetermined conditions.
PTC Therapeutics director reports charitable stock gift
A director of PTC Therapeutics, Inc. (PTCT) reported a bona fide gift of 867 shares of the company’s common stock on 11/20/2025. The transaction was coded as a gift and priced at $0, reflecting that no sale proceeds were received. After this transaction, the reporting person beneficially owns 8,000 shares of PTC Therapeutics common stock in direct ownership. The filing is made on Form 4 for a single reporting person and indicates the shares were donated to a charitable organization.
PTC Therapeutics executive reports option exercise and share sales
The Executive Vice President and Chief Legal Officer of PTC Therapeutics, Inc. (PTCT) reported transactions dated 11/17/2025. The officer exercised a stock option for 2,812 shares of common stock at an exercise price of $25.69 per share, then sold 1,843 shares at a weighted average price of $75.64, 777 shares at $76.53, and 192 shares at $77.18, all under a Rule 10b5-1 trading plan adopted on December 5, 2024.
After these transactions, the officer beneficially owned 103,901 shares of common stock directly and 25,314 stock options with an exercise price of $25.69 expiring on 02/14/2034. The reported option grant was made on February 15, 2024 and vests over four years, with 25% vesting on February 15, 2025 and 6.25% of the original grant vesting at the end of each three-month period thereafter.
PTC Therapeutics (PTCT) filed its Q3 2025 10‑Q, reporting a return to profitability for the quarter and sharply higher year‑to‑date results. Q3 revenue was $211.0 million (vs. $196.8 million a year ago), and net income was $15.9 million (vs. a $106.7 million loss). Diluted EPS was $0.20.
For the first nine months, revenue reached $1.566 billion (vs. $593.6 million), driven by $998.4 million of collaboration and license revenue tied to the Novartis votoplam agreement, with net income of $817.6 million. Cash and cash equivalents were $672.6 million and marketable securities $1.015 billion. The stockholders’ deficit narrowed to $(155.8) million from $(1.10) billion at year‑end.
Product and pipeline updates include FDA approval of Sephience for PKU in July 2025 (and EC authorization in June 2025), EC non‑renewal of Translarna in March 2025 with certain EU country exceptions, and FDA acceptance of the resubmitted Translarna NDA in October 2024. The FDA approved the AADC gene therapy in the U.S. in November 2024 (marketed as Kebilidi). The FDA issued a complete response letter for vatiquinone in August 2025. The Novartis votoplam deal closed in January 2025 with a $1.0 billion upfront payment.
PTC Therapeutics filed an 8-K announcing financial results for the quarter ended September 30, 2025. The full details are provided in a press release furnished as Exhibit 99.1.
The company will host a conference call on November 4, 2025 at 4:30 p.m. Eastern to review the results and other updates. Items 2.02 and 7.01, and Exhibit 99.1, are furnished and not deemed filed under Section 18 of the Exchange Act.